<DOC>
	<DOCNO>NCT01666769</DOCNO>
	<brief_summary>Determine proper dose micafungin child support extracorporeal membrane oxygenation ( ECMO ) .</brief_summary>
	<brief_title>Pharmacokinetics Micafungin Children Extracorporeal Membrane Oxygenation</brief_title>
	<detailed_description>Extracorporeal membrane oxygenation ( ECMO ) cardiopulmonary bypass device provide life-saving , complete respiratory cardiac support child suffer refractory heart lung failure . While ECMO , child increase risk infection , include fungal infection . Antifungal prophylaxis potentially reduce burden disease child ECMO . Because fungal infection result biofilms difficult treat , treatment include antifungal medication also removal large intravenous line . However , catheter removal child ECMO impossible ; therefore , therapy relies upon optimal antifungal management alone . Micafungin antifungal medication work well common fungal infection show safe child . Micafungin may particularly efficacious child ECMO drug 's ability penetrate biofilms . However , ECMO circuit know substantially alter drug level many drug , result important dosing change . Appropriate micafungin dose set unknown sub-optimal dosing might result therapeutic prophylactic failure . Standard dose micafungin 4 2 mg per kilogram body weight give intravenously daily treatment prophylaxis , respectively . Based preliminary data model study , investigator hypothesize 8 4 mg per kilogram give daily achieve proper drug level respectively treat prevent fungal infection child 2 year age support ECMO . Because ECMO circuit less impact volume distribution large child , investigator hypothesize child 2 18 year old , standard dose micafungin achieve proper drug concentration . Investigators hold FDA investigational new drug application ( IND # 115255 ) give micafungin child ECMO dose describe . Blood sample collect specific time around first fourth micafungin dos describe pharmacokinetics drug extraction ECMO circuit .</detailed_description>
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Candidiasis , Invasive</mesh_term>
	<mesh_term>Micafungin</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<criteria>&lt; = 17.85 year time enrollment . Sufficient venous access permit administration study medication . Supported either venoarterial ( VA ) venovenous ( VV ) ECMO . Availability willingness parent/legal guardian provide write informed consent . For treatment dose arm : confirm suspected infection Subject history anaphylaxis attribute echinocandin . Any concomitant condition , opinion investigator would preclude subject 's participation study . Previous participation study . Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Extracorporeal membrane oxygenation</keyword>
	<keyword>ECMO</keyword>
	<keyword>Extracorporeal life support</keyword>
	<keyword>Micafungin</keyword>
	<keyword>Mycamine</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>